![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif)
belinostat A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif)
Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif) | PXD101 | | ![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115065722im_/http://www.cancer.gov/images/spacer.gif) |